Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria R Farcet

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Transfusion|February 22, 2021
Longitudinal analysis of SARS-CoV-2 antibodies in 8000 U.S. first-time convalescent plasma donationsMichael Karbiener, Maria R Farcet, Reinhard Ilk, et al.
Transfusion|August 15, 2020
Antibody-enhanced hepatitis E virus nanofiltration during the manufacture of human immunoglobulinAnna-Maria Kapsch, Maria R Farcet, Andreas Wieser, et al.
The Journal of Infectious Diseases|April 9, 2024
Neutralization of Rubella Vaccine Virus and Immunodeficiency-Related Vaccine-Derived Rubella Viruses by Intravenous ImmunoglobulinsMin-Hsin Chen, Ludmila Perelygina, LiJuan Hao, et al.
Transfusion|February 21, 2012
Chikungunya virus and the safety of plasma productsSandra M Leydold, Maria R Farcet, Johanna Kindermann, et al.
The Journal of Infectious Diseases|October 3, 2017
Measles Virus Neutralizing Antibodies in Intravenous Immunoglobulins: Is an Increase by Revaccination of Plasma Donors Possible?Jens Modrof, Björn Tille, Maria R Farcet, et al.
Communications Medicine|May 23, 2022
Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adultsAngelika Wagner, Angela Guzek, Johanna Ruff, et al.
Virology Journal|April 18, 2014
Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID miceChristine Hohenadl, Walter Wodal, Astrid Kerschbaum, et al.
Ebiomedicine|August 14, 2021
B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19Andreas Zollner, Christina Watschinger, Annika Rössler, et al.
Frontiers in Medicine|March 4, 2022
SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 YearErika Garner-Spitzer, Angelika Wagner, Michael Kundi, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Transfusion|February 22, 2021
Longitudinal analysis of SARS-CoV-2 antibodies in 8000 U.S. first-time convalescent plasma donationsMichael Karbiener, Maria R Farcet, Reinhard Ilk, et al.
Transfusion|August 15, 2020
Antibody-enhanced hepatitis E virus nanofiltration during the manufacture of human immunoglobulinAnna-Maria Kapsch, Maria R Farcet, Andreas Wieser, et al.
The Journal of Infectious Diseases|April 9, 2024
Neutralization of Rubella Vaccine Virus and Immunodeficiency-Related Vaccine-Derived Rubella Viruses by Intravenous ImmunoglobulinsMin-Hsin Chen, Ludmila Perelygina, LiJuan Hao, et al.
Transfusion|February 21, 2012
Chikungunya virus and the safety of plasma productsSandra M Leydold, Maria R Farcet, Johanna Kindermann, et al.
The Journal of Infectious Diseases|October 3, 2017
Measles Virus Neutralizing Antibodies in Intravenous Immunoglobulins: Is an Increase by Revaccination of Plasma Donors Possible?Jens Modrof, Björn Tille, Maria R Farcet, et al.
Communications Medicine|May 23, 2022
Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adultsAngelika Wagner, Angela Guzek, Johanna Ruff, et al.
Virology Journal|April 18, 2014
Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID miceChristine Hohenadl, Walter Wodal, Astrid Kerschbaum, et al.
Ebiomedicine|August 14, 2021
B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19Andreas Zollner, Christina Watschinger, Annika Rössler, et al.
Frontiers in Medicine|March 4, 2022
SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 YearErika Garner-Spitzer, Angelika Wagner, Michael Kundi, et al.
Pageof 4